MAGEA3 and melanoma: Similarly, in the IMvigor210 (anti–PD-L1), GSE35640 (MAGE-A3), Melanoma-GSE78220 (anti–PD-1), and Melanoma-GSE100797 (ACT) cohorts, the low-risk group also presented higher response rates to immunotherapy (Figures 9G–J); however, these differences did not reach statistical significance (P > 0.05).